SMYD3 promotes colon adenocarcinoma (COAD) progression by mediating cell proliferation and apoptosis.

Colon adenocarcinoma (COAD) is a type of common malignant tumor originating in the digestive tract. Recently, targeted therapy has had significant effects on the treatment of COAD. However, more effective molecular targets need to be developed.